Moving CAR T-cell therapy to earlier treatment lines is crucial. This approach targets cancer before it develops resistance and, more importantly, utilizes patient T-cells that are healthier and more effective, not having been damaged by extensive prior chemotherapy regimens.

CELMoDs are being actively trialed as a maintenance therapy after CAR T-cell treatment. The strategy is to leverage the CELMoDs' ability to enhance T-cell function and upregulate effector T-cells to boost the activity and persistence of the CAR-T product, potentially leading to more durable responses and preventing relapse.

Unlike IMiDs (lenalidomide) which only close the Cereblon E3 ligase complex by 15-20%, mezigdemide achieves 100% closure. This leads to more robust degradation of key proteins, causing powerful direct myeloma cell destruction and enhanced immune activation, earning it the nickname 'CAR T in a pill.'

Unlike CAR-T therapies that rely on a limited number of engineered cells, T-cell engagers activate the body's entire T-cell repertoire. This vast pool of effector cells makes exhaustion a negligible issue, as only a small fraction is engaged at any time, ensuring a sustained attack on cancer cells.

Unlike older IMiDs where T-cell effects are secondary, CELMoDs have a powerful, independent pro-T-cell mechanism. This dual action is so significant that in the future, CELMoDs will be prescribed not just for their direct anti-myeloma effects, but specifically to enhance the efficacy of T-cell therapies like CAR-T and bispecific antibodies.

In a heavily pretreated population, mezigdemide plus dexamethasone achieved a 50% response rate in patients refractory to prior BCMA-based approaches, including antibody-drug conjugates, bispecifics, and CAR T-cell therapy. This demonstrates a distinct mechanism that can overcome resistance to the latest immunotherapies.

During the pandemic, a multicenter mezigdomide trial had zero COVID-19 deaths. This contrasts sharply with bispecific antibody trials in similar populations, which reported significant COVID mortality. This suggests CELMoDs have a more favorable immune profile for managing viral infections in immunocompromised patients.

Quell differentiates its CAR-Treg therapy by aiming to restore immune balance. Unlike B-cell depletion therapies (CAR-T), their approach uses CD19 on B-cells as an activation signal. This creates a local suppressive environment that 'chills' multiple pathogenic cell types (T-cells, B-cells, macrophages) instead of killing just one.

Rather than expecting cell therapies (CAR-T, TIL) to eradicate every cancer cell, Dr. Radvanyi reframes them as powerful adjuvants. Their role is to inflict initial damage, kill tumor cells, and release antigens, creating an opportunity to prime a broader, secondary immune response with other modalities like vaccines or checkpoint inhibitors.